性病学
天疱疮
医学
指南
皮肤病科
欧洲联盟
副肿瘤性天疱疮
病理
免疫学
自身抗体
经济政策
业务
抗体
作者
Michael Hertl,Hana Jedličková,Sarolta Kárpáti,Branka Marinović,Soner Uzun,Savaş Yaylı,Daniel Mimouni,Luca Borradori,Claudio Feliciani,D. Ioannides,P. Joly,Cezary Kowaléwski,Giovanna Zambruno,Detlef Zillikens,Marcel F. Jonkman
摘要
Abstract Background Pemphigus encompasses a group of life‐threatening autoimmune bullous diseases characterized by blisters and erosions of the mucous membranes and skin. Before the era of immunosuppressive treatment, the prognosis of pemphigus was almost fatal. Due to its rarity, only few prospective controlled therapeutic trials are available. Objectives For this reason, a group of European dermatologists with a long‐standing interest and expertise in basic and clinical pemphigus research has sought to define diagnostic and therapeutic guidelines for the management of patients with pemphigus. Results This group identified the statements of major agreement or disagreement regarding the diagnostic and therapeutic management of pemphigus. The revised final version of the pemphigus guideline was finally passed on to the European Dermatology Forum ( EDF ) for a final consensus with the European Academy of Dermatology and Venereology ( EADV ) and the European Union of Medical Specialists ( UEMS ).
科研通智能强力驱动
Strongly Powered by AbleSci AI